MarginsXMarginsX
Home › Markets › Health Care › ALXO

ALX Oncology Holdings Inc. (ALXO)

ALXO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.00
-3.85% on the day
Market cap
$124.9M
Micro cap
Revenue · 2022
$0
Prior year not contiguous
Net income · 2022
-$123.5M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1810182/000095017023007013/0000950170-23-007013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerALXO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001810182
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2022

LineValue
Revenue$0
Net income-$123.5M
Operating income-$127.4M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$48.8M
Total assets$306.5M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
3.8 months
$22.7M cash at June 30, 2026
Share count, 1 year
+158.2%
2025-08-05 to 2026-07-30 · +236.0% over 3 years
Going-concern doubt
No
10-Q filed August 6, 2026
Insider net buying, 12 months
$5.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-06
Cash and burn$22.7M cash; operating cash flow -$17.7M a quarter.Report 2026-06-30
Shares outstanding138,276,997 (2026-07-30); 53,551,134 a year earlier; 41,151,819 three years earlier.Cover page 2026-07-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-01-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5.0M, sold $43K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$18.0M-$16.1M$22.7M$10.2MNeeds four quarters10-Q 2026-08-06
Q1 2026
2026-03-31
Not filed-$17.9M-$18.6M$32.3M$8.9MNeeds four quarters10-Q 2026-08-06
Q4 2025
2025-12-31
Not filed-$22.8M-$19.0M$16.4M$10.2MNeeds four quarters10-K 2026-03-09
Q3 2025
2025-09-30
Not filed-$22.1M-$17.1M$23.4M$10.6MNeeds four quarters10-Q 2025-11-07
Q2 2025
2025-06-30
Not filed-$25.9M-$23.4M$19.3M$10.6MNeeds four quarters10-Q 2026-08-06
Q1 2025
2025-03-31
Not filed-$30.8M-$24.7M$20.6M$10.6MNeeds four quarters10-Q 2026-08-06
Q4 2024
2024-12-31
Not filed-$29.2M-$32.0M$17.6M$10.6MNeeds four quarters10-K 2026-03-09
Q3 2024
2024-09-30
Not filed-$30.7M-$25.4M$16.1M$10.6MNeeds four quarters10-Q 2025-11-07

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-01-30
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-08-06
Latest current report8-K2026-11-16
Latest proxyDEF 14A2026-04-20

Source: SEC EDGAR submissions feed, 422 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.0%
1 month+6.1%
3 months-46.4%
Year to date-8.0%
1 year-14.8%
From 52-week high-60.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AKBAAkebia Therapeutics Inc.$0.4486-5.40%$124.6M
SPRBSpruce Biosciences Inc.$42.25-2.45%$121.4M
CNTNCanton Strategic Holdings Inc.$1.64-4.09%$130.7M
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
UPBUpstream Bio Inc.$2.15-22.66%$117.8M
MENSJyong Biotech Ltd.$1.77+0.57%$134.6M
IMUXImmunic Inc.$7.23-3.86%$114.8M
MSLESatellos Bioscience Inc.$6.47-2.34%$137.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier